Phase II Randomized, Multicenter, Double-blind, Doubledummy, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder
Latest Information Update: 24 Aug 2026
At a glance
- Drugs APSTZD-Apsen Farmaceutica (Primary) ; Zolpidem
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Apsen Farmaceutica
Most Recent Events
- 21 Aug 2026 Planned End Date changed from 23 Sep 2027 to 1 Dec 2027.
- 21 Aug 2026 Planned primary completion date changed from 23 Sep 2027 to 1 Dec 2027.
- 21 Aug 2026 Status changed from not yet recruiting to recruiting.